loading page

Mepolizumab -- therapeutic strategy for a paediatric patient with eosinophilic granulomatosis with polyangiitis
  • +5
  • Lota Ozola,
  • Elīna Aleksejeva,
  • Diāna Stoldere,
  • Ineta Grantiņa,
  • Zane Dāvidsone,
  • Ruta Šantere,
  • Ieva Cīrule,
  • Alvils Krams
Lota Ozola
Bērnu klīniskā universitātes slimnīca
Author Profile
Elīna Aleksejeva
Bērnu klīniskā universitātes slimnīca
Author Profile
Diāna Stoldere
Bērnu klīniskā universitātes slimnīca
Author Profile
Ineta Grantiņa
Bērnu klīniskā universitātes slimnīca
Author Profile
Zane Dāvidsone
Bērnu klīniskā universitātes slimnīca
Author Profile
Ruta Šantere
Bērnu klīniskā universitātes slimnīca
Author Profile
Ieva Cīrule
Bērnu klīniskā universitātes slimnīca
Author Profile
Alvils Krams
Rīgas Austrumu klīniskā universitātes slimnīca
Author Profile

Abstract

Eosinophilic granulomatosis with polyangiitis (EGPA; formerly known as Churg-Strauss syndrome) is classified as an anti-neutrophil cytoplasmic antibody (ANCA)-associated small vessel vasculitis. It is a multisystem disorder and can affect every organ system. EGPA is a rare disease, with an estimated prevalence of 1/70,000–100,000 in Europe. As its onset usually occurs in adulthood, data from paediatric patients are limited. We present here a very rare practical EGPA clinical case involving a paediatric patient. Presently, data on mepolizumab usage in paediatric patients are limited, with only a few case reports published.

Peer review status:UNDER REVIEW

11 Jan 2022Submitted to Pediatric Pulmonology
12 Jan 2022Assigned to Editor
12 Jan 2022Submission Checks Completed
12 Jan 2022Reviewer(s) Assigned